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Objective: To determine the effects of patent or diseased aorta-coronary
bypass grafts and retrograde cardioplegia on mortality during reoperative
coronary bypass surgery.
Methods: We conducted a retrospective review of prospectively gathered
data, supplemented by systematic chart review, of all patients (n = 744)
undergoing reoperative coronary bypass surgery at our institution between
1990 and 1997. Independent predictors of survival were determined by step-
wise logistic regression analysis.
Results: At least one patent or stenosed graft to the left anterior descending
artery was present in 50% of patients, to the circumflex territory in 27% of
patients, and to the right coronary artery territory in 33% of patients. The
previous left anterior descending graft was a saphenous vein in 82% and a
left internal thoracic artery in 18% of patients. In-hospital mortality occurred
in 42 (5.6%) patients. Patent or diseased grafts of any coronary artery terri-
tory did not significantly increase the risk of mortality. Retrograde cardio-
plegia use increased in more recent years, was more frequent in patients with
stenosed grafts, and was associated with improved survival. Independent
predictors of mortality were as follows (with odds ratios and 95% confidence
intervals in parentheses): failure to use retrograde cardioplegia (odds ratio
2.81; 1.28-6.20), New York Heart Association class (odds ratio 2.69; 1.25-
5.81), peripheral vascular disease (odds ratio 2.60; 1.25-5.41), and left ven-
tricular grade (2.07; 1.31-3.27).
Conclusions: In this series, patent or stenosed grafts were not associated with
an increased risk of mortality during reoperative coronary bypass surgery,
possibly because of increased use of retrograde cardioplegia in this patient
group. We strongly recommend the routine use of retrograde cardioplegia
during redo coronary bypass surgery. (J Thorac Cardiovasc Surg
2001;121:83-90)
Michael A. Borger, MD
Vivek Rao, MD, PhD
Richard D. Weisel, MD
Alejandro A. Floh, BSc
Gideon Cohen, MD
Christopher M. Feindel, MD
Hugh E. Scully, MD
Lynda L. Mickleborough, MD
Terrence M. Yau, MD, MSc
83
SURGERY FOR ACQUIRED
CARDIOVASCULAR DISEASE
REOPERATIVE CORONARY BYPASS SURGERY: EFFECT OF PATENT GRAFTS AND RETROGRADE
CARDIOPLEGIA
From the Division of Cardiovascular Surgery, Toronto General
Hospital, University Health Network, and the Department of
Surgery, University of Toronto, Toronto, Ontario, Canada.
Supported in part by the Heart and Stroke Foundation of Ontario
(HSFO). M.A.B. is a Research Fellow of the HSFO. R.D.W. is a
Career Investigator of the HSFO.
Read at the Eightieth Annual Meeting of The American Association
for Thoracic Surgery, Toronto, Ontario, Canada, April 30–May 3,
2000.
Received for publication May 4, 2000; revisions requested July 31,
2000; revisions received Aug 28, 2000; accepted for publication
Sept 3, 2000.
Address for reprints: Terrence M. Yau, MD, MSc, Toronto General
Hospital, EN 13-239, 200 Elizabeth St, Toronto, Ontario, Canada
M5G 2C4 (E-mail: terry.yau@utoronto.ca).
Copyright © 2001 by The American Association for Thoracic
Surgery
0022-5223/2001 $35.00 + 0 12/6/111382
doi:10.1067/mtc.2001.111382
R eoperative coronary bypass grafting (redo-CABG)is an important clinical problem for cardiac sur-
geons. The number of redo-CABGs may be rising over
time,1 and the risk profile of patients undergoing reop-
eration is increasing.2,3 Several previous studies have
demonstrated an increased risk for reoperation in
patients with patent or diseased CABGs, particularly
atherosclerotic saphenous vein grafts.4-7 Retrograde
cardioplegia has been proposed as a method of decreas-
ing the risk of redo-CABG.8-10
We undertook this study to determine (1) whether
patent or diseased grafts increase the risk of mortality
during redo-CABG and (2) whether retrograde cardio-
plegia mitigates this increased risk.
Methods
Preoperative, perioperative, and postoperative data were
collected prospectively on all patients and entered into our
institutional computerized registry. All patients undergoing
redo-CABG (at least one prior CABG procedure) from 1990
to 1997 were identified. Patients undergoing concomitant
valvular, aneurysmal, or extracardiac procedures were
excluded.
A systematic chart review was performed on all redo-
CABG patients identified (n = 744), with a focus on the sta-
tus of previous CABGs. Previous grafts were classified as
patent (no stenosis), stenosed (at least one stenosis > 50% of
the luminal diameter), or occluded. Graft location was classi-
fied according to the three major coronary artery territories—
left anterior descending (LAD), circumflex, and right coro-
nary artery (RCA). Patients with more than one graft to a
territory were assigned the highest risk present for that terri-
tory, where estimated risk was stenosed > patent > occluded.
For example, a patient with one stenosed and one patent (non-
stenosed) graft to the circumflex territory was considered to
be in the stenosed circumflex group.
Anesthetic and surgical management. Pulmonary artery
catheters and arterial cannulas were used for perioperative
monitoring. Before 1995, our standard cardiac anesthetic
consisted of high-dose fentanyl and midazolam for induction
and isoflurane for maintenance. Since 1995, we have aimed
for early extubation in all patients with an anesthetic consist-
ing of low-dose fentanyl for induction and isoflurane and
propofol for maintenance.11
Access to the mediastinum was through a median sternoto-
my in nearly all patients. Femoral vessels were not routinely
exposed. Arterial cannulation was performed via the ascend-
ing aorta or aortic arch. A single, two-staged right atrial can-
nula was used for venous drainage. The hematocrit value was
maintained between 20% and 25% during cardiopulmonary
bypass (CPB), pump flow rates between 2.0 and 2.5 L · min–1
· m–2, and mean arterial pressure between 60 and 80 mm Hg.
Systemic body temperature was allowed to drift to 34°C, with
active rewarming at the end of CPB.
The “no-touch” technique was used for dissection of medi-
astinal structures in patients with diseased grafts,10 with
manipulation of diseased grafts being avoided before admin-
istration of cardioplegic solution. Diseased grafts were ligat-
ed and removed after cardioplegic solution was administered,
except when a left internal thoracic artery (LITA) was being
used to replace a large, noncritically stenosed vein graft to the
LAD.12 Coronary bypass anastomoses were performed dur-
ing a single period of aortic crossclamping. We used the LITA
to bypass the LAD in the majority of patients without a pre-
vious LITA graft. In those patients with a functioning previ-
ous LITA graft, a temporary clamp was applied to the LITA
during administration of cardioplegic solution.
Myocardial protection. All patients received blood-based
cardioplegic solution at a ratio of 4:1 (blood to crystalloid
solution) before 1996 and 8:1 since 1996. Our crystalloid
component consisted of potassium chloride and magnesium
sulphate.13 Cardioplegia temperature and delivery technique
were according to surgeon preference. Antegrade cardiople-
gia was administered via the aortic root at a pressure of 70
mm Hg. One liter of cardioplegic solution was given to
achieve myocardial arrest, followed by repeated doses of 300
mL after each proximal anastomosis or every 20 minutes
thereafter. When used, retrograde cardioplegia was adminis-
tered almost continuously via a self-inflating coronary sinus
catheter to a maximum flow of 200 mL/min or a maximum
coronary sinus pressure of 40 mm Hg. “Combination” car-
dioplegia consisted of antegrade cardioplegia to achieve
myocardial arrest followed by retrograde cardioplegia with or
without antegrade perfusion of completed vein grafts.
Statistical analysis. All statistical analyses were per-
formed with the SAS system (SAS Institute, Inc, Cary, NC).
Categorical variables are expressed as percentages and were
evaluated with χ2 or Fisher exact tests where appropriate.
Continuous variables are expressed as mean ± standard devi-
ation (SD) and were evaluated by the Student t tests. Possible
risk factors for in-hospital mortality were analyzed univari-
ately (see the appendix). All variables suggested by the uni-
variate analysis (P < .25) or those judged to be clinically
important were entered into a stepwise multivariable logistic
regression analysis model. The model with the best Hosmer-
Lemeshow goodness-of-fit statistic and receiver operator
characteristic curve was chosen, as previously described.14
Results
A total of 744 patients underwent redo-CABG at our
institution between 1990 and 1997, representing 7.0%
of the entire CABG population. The number of redo-
CABGs performed per year, as well as the percentage
of CABG procedures that were reoperative, remained
relatively constant over this time period. The number of
previous CABG procedures was one in 723 patients,
two in 20 patients, and three in 1 patient. The mean (±
SD) interval between operations was 11.4 ± 4.9 years.
The number of distal anastomoses per patient was 3.2
± 1.0. At reoperation, the LITA was used to bypass the
LAD in 494 (66%) patients. The mean aortic cross-
clamp and CPB times were 68 ± 23 and 103 ± 36 min-
utes, respectively.
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A perioperative myocardial infarction occurred in 49
(6.6%) patients and postoperative low cardiac output
syndrome occurred in 166 (22.3%) patients. An intra-
aortic balloon pump was inserted in the operating room
or postoperatively in 144 (19.4%) patients. Seventeen
(2.3%) patients required resternotomy for bleeding.
Stroke occurred in 17 (2.3%) patients and deep sternal
wound infection in 5 (0.7%) patients. In-hospital mor-
tality occurred in 42 (5.6%) patients and is discussed in
more detail below.
Previous graft status. A patent or stenosed graft to
the LAD was present in 370 (50%) patients. The previ-
ous graft to the LAD was a saphenous vein in 82% of
patients and a LITA in 18%. Previous saphenous vein
grafts were more likely to be stenosed (40%) or occlud-
ed (50%) than LITA grafts (9% and 33%, respectively;
P < .001). The LITA was injured during resternotomy
in 10 patients (12.5% of all patients with patent or
stenosed LITA grafts), of whom 1 patient died. The
right ventricle was injured during resternotomy in 9
patients, of whom 2 died.
At least one patent or stenosed graft to the circumflex
territory was present in 199 (27%) patients and to the
RCA territory in 246 (33%) patients. Previous grafts to
the circumflex or RCA territory were saphenous veins
in the vast majority of patients.
Table I displays mortality rates according to the sta-
tus of previous grafts. We were unable to demonstrate
a statistically significant effect of previous graft sta-
tus—to the LAD, circumflex, or RCA territory—on
mortality. Although the differences were not statistical-
ly significant, it appears that patients with no previous
LAD graft had the highest risk of mortality, followed
by patients with stenosed grafts to the circumflex and
LAD coronary arteries.
Myocardial protection. As stated previously, the
method of cardioplegia administration was at the discre-
tion of the surgeon. Antegrade cardioplegia alone was
used in 60% of patients, retrograde cardioplegia alone in
15%, and a combination of the two methods in 25%. The
cardioplegic solution was warm (>35°C) in 3% of
patients, tepid (20°C-35°C) in 8%, and cold (<20°C) in
89%. Cardioplegic solution was administered intermit-
tently in 67% of patients and near continuously in 33%.
Fig 1 displays the use of retrograde cardioplegia,
either alone or in combination with antegrade cardio-
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Table I. Incidence of in-hospital mortality according to previous graft status during redo-CABG (n = 744) 
Status of previous graft (%)
Territory None Occluded Stenosed Patent P value
LAD 10.7 3.8 7.3 4.7 .10
Circumflex 4.5 5.5 8.6 5.1 .5
RCA 4.8 7.0 4.0 3.5 .4
LAD, Left anterior descending coronary artery; RCA, right coronary artery.
Fig 1. Prevalence of retrograde cardioplegia use (alone or in combination with antegrade cardioplegia) during redo-
CABG surgery over time.
plegia, over time. There was a significant increase in the
use of retrograde cardioplegia for redo-CABG surgery
over the period of this study (P < .001). We also exam-
ined the relationship between retrograde cardioplegia
use and status of previous grafts. Fig 2 reveals that ret-
rograde cardioplegia, alone or in combination with ante-
grade cardioplegia, was more likely to be used in
patients with at least one stenosed graft (P < .001).
Retrograde cardioplegia, alone or combined, resulted
in a significant reduction in mortality (P < .05, Fig 3).
However, the use of retrograde cardioplegia did not sig-
nificantly decrease the risk of myocardial infarction,
which occurred in 5.3% of antegrade procedures, 5.3%
of retrograde procedures, and 7.8% of combined pro-
cedures (P = .5). Likewise, retrograde cardioplegia did
not reduce the incidence of low cardiac output syn-
drome (21% for antegrade, 24% for retrograde, and
22% for combined, P = .5).
Predictors of mortality. Hospital mortality occurred
in 42 (5.6%) patients. The association between mortali-
ty and each of the variables listed in the appendix was
first analyzed univariately. Significant (P < .05) univari-
ate predictors of mortality were female sex, increased
age, urgent timing, Canadian Cardiovascular Society
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Fig 2. Use of cardioplegia delivery techniques according to the presence or absence of one or more stenosed grafts.
Retrograde cardioplegia, alone or in combination with antegrade cardioplegia, was used more frequently in patients
with stenosed grafts.
Fig 3. In-hospital mortality according to cardioplegia delivery technique.
angina class, New York Heart Association heart failure
class, increasing left ventricular dysfunction (left ven-
tricular grade), peripheral vascular disease, systemic
hypothermia during CPB, failure to use a LITA graft,
and failure to use retrograde cardioplegia. The surgeon
was also a significant univariate predictor of mortality
(P = .03) before risk adjustment by multivariable tech-
niques. Mortality rates for the 8 surgeons who per-
formed more than 10 reoperative procedures ranged
from 1.3% to 15%.
Fig 4 displays the independent predictors of mortali-
ty, as determined by multivariable logistic regression
analysis. The risk factors for mortality, in decreasing
order of magnitude, were failure to use retrograde car-
dioplegia, increasing New York Heart Association class,
peripheral vascular disease, and increasing left ventric-
ular dysfunction (left ventricular grade). After adjust-
ment for these risk factors, the operating surgeon was
not an independent predictor of mortality. The area
under the receiver operator characteristic curve was
0.741 and the Hosmer-Lemeshow goodness-of-fit sta-
tistic was 0.611 for our logistic regression model, indi-
cating good discrimination and precision.
Discussion
Redo-CABG is an important clinical entity. Previous
studies have noted an increase in the prevalence of
redo-CABG surgery over time as the age of our patient
population increases.3,15,16 However, increasing use of
arterial conduits17 and lipid-lowering agents18 may
result in a plateau in the number of reoperative proce-
dures, a pattern we have noted in our own institution.2
Several investigators have noted an increased risk
profile for redo-CABG patients over time.2,3,16 We
recently examined 1230 consecutive redo-CABG
patients over a 16-year period and found increased
age, left ventricular dysfunction, severity of symp-
toms, extent of coronary artery disease, and
urgent/emergency timing in more recent years.2
Despite the increase in risk profile, however, morbid-
ity and mortality remained constant or decreased
throughout the study.
Redo-CABG surgery may be required as a result of
graft disease, progression of native coronary athero-
sclerosis, or a combination of these factors.3,4,19 Of
these three indications, vein graft disease is by far the
most common.3,4,19 Approximately 40% of saphenous
vein grafts are occluded 10 years after CABG surgery
and a further 30% are stenotic, predominantly because
of vein graft atherosclerosis.4
Several previous studies have noted an increased risk
of mortality in redo-CABG patients with patent or dis-
eased grafts.4-7 The increased risk is primarily due to
atheroembolism from saphenous vein grafts, a widely
recognized complication.5,10,20 Patent LITA grafts may
also increase risk due to graft injury during dissection.21
Retrograde cardioplegia may decrease the risk of
atheroembolism during redo-CABG. Retrograde deliv-
ery has been hypothesized to result in less embolization
than antegrade delivery,22 and anecdotal evidence sug-
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Fig 4. Independent predictors of in-hospital mortality. C.I.’s, Confidence intervals; NYHA class, New York Heart
Association heart failure class; PVD, peripheral vascular disease; LV grade, left ventricular ejection fraction, where
grade I is 60% or more, grade II is 40% to 59%, grade III is 20% to 39%, and grade IV is less than 20%.
gests that retrograde delivery of cardioplegic solution
can dislodge atheroemboli that have already oc-
curred.21 Previous studies, with relatively small num-
bers of patients undergoing reoperations, have suggest-
ed that retrograde cardioplegia decreases the use of
intra-aortic balloon pumping8 and mortality.9,10 We
therefore analyzed a large cohort of redo-CABG
patients to determine whether patent or stenotic grafts
increase the risk of mortality and whether retrograde
cardioplegia mitigates this risk.
We were unable to demonstrate a statistically signifi-
cant effect of previous graft status, to any coronary ter-
ritory, on mortality (Table I). We were surprised to find
that patients with the highest risk of mortality were not
those with stenosed grafts to the LAD, but rather
patients without a previous LAD graft. However, this
may simply be a reflection of marginal coronary anato-
my in these patients. Stenosed grafts to the RCA or cir-
cumflex territory did not result in a significantly
increased risk of mortality.
As expected, we found a higher incidence of stenosis
in saphenous vein grafts to the LAD when compared
with LITAs. Although injury to the LITA occurred in
12.5% of patients at risk in this study, only one death
occurred in this group. We therefore concur with previ-
ous investigators that a functioning LITA graft is not a
contraindication to redo-CABG.21
Our use of retrograde cardioplegia in redo-CABG
patients increased over time (see Fig 1) as the benefits
of this technique became more apparent in the litera-
ture. We were more likely to use retrograde delivery in
patients with one or more stenosed grafts (see Fig 2).
Retrograde cardioplegia, alone or in combination with
antegrade cardioplegia, resulted in a significant reduc-
tion in mortality (see Fig 3). In addition, multivariable
analysis revealed that retrograde cardioplegia was the
most significant independent predictor of survival (Fig
4). Although surgeons differed with regard to which
cardioplegia delivery technique was used, individual
surgeon was not an independent predictor of mortality.
In addition, the surgeon with the second lowest mortal-
ity in our series (2.8%) used antegrade cardioplegia
almost exclusively. Therefore, we do not believe that
the benefit of retrograde cardioplegia is simply a sur-
geon-specific finding.
We were unable to demonstrate a beneficial effect of
retrograde cardioplegia on the incidence of myocardial
infarction or low cardiac output syndrome. However,
this lack of effect may be due to the higher risk profile
of the retrograde cardioplegia group, that is, more
patients with stenotic vein grafts.
Fig 3 reveals that the lowest risk of mortality
occurred in patients receiving retrograde cardioplegia
alone. However, previous studies by our group have
revealed that isolated retrograde cardioplegia may
result in inadequate myocardial perfusion. In a ran-
domized trial of 107 patients undergoing CABG,23 we
found that retrograde cardioplegia resulted in increased
myocardial lactate production, increased creatine
kinase MB release, and decreased adenosine triphos-
phate levels when compared with antegrade cardiople-
gia. In addition, we used intraoperative contrast
echocardiography to demonstrate that retrograde car-
dioplegia resulted in poor perfusion of the right ventri-
cle.24 Antegrade perfusion of the saphenous vein graft
to the RCA resulted in a marked improvement in right
ventricular perfusion.24 Therefore, the optimal myocar-
dial protection strategy for redo-CABG may be retro-
grade cardioplegia supplemented by antegrade perfu-
sion of new vein grafts, in particular to the RCA.
Conclusions
In this large retrospective study, we were unable to
detect a significantly increased risk of in-hospital mortal-
ity for patients with patent or stenosed grafts. The lack of
association may be due to our increased use of retrograde
cardioplegia in patients with stenosed grafts. Retrograde
cardioplegia, alone or in combination with antegrade car-
dioplegia, resulted in a significant reduction in mortality.
We therefore recommend the use of retrograde cardiople-
gia in all patients undergoing redo-CABG. 
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Appendix
Variables assessed in predictive models
Year of redo-CABG operation
Time since previous CABG operation
Number of previous CABG operations
Sex
Age
Left ventricular grade: Left ventricular ejection fraction, as
assessed by angiography or 2-dimensional echocardiography,
where grade I ≥ 60%, grade II = 40% to 59%, grade III = 20%
to 39%, and grade IV < 20%
Recent (<30 days) myocardial infarction
Timing: Elective, semi-urgent (operation during same hos-
pitalization for cardiac event), urgent (operation < 72 hours of
cardiac event), and emergency (operation < 12 hours of car-
diac event)
Canadian Cardiovascular Society angina class
New York Heart Association heart failure class
Congestive heart failure: History of hospital admission for
congestive heart failure 
Renal failure: Serum creatinine > 200 µmol/L or history of
renal failure 
Diabetes mellitus
Hypertension
Hypercholesterolemia
Chronic obstructive pulmonary disease
Peripheral vascular disease: History of peripheral or
carotid vascular disease 
Previous stroke or transient ischemic attack
CPB temperature: Normothermia (minimum systemic tem-
perature > 35°C) or mild (30°-35°C), moderate (20°-29°C) or
profound (<20°C) hypothermia
Cardioplegia temperature: Cold (<20°C), tepid (20°C-
35°C), or warm (>35°C) blood cardioplegic solution
Cardioplegia delivery: (1) Antegrade, retrograde, or com-
bined (antegrade and retrograde) cardioplegia; (2) intermit-
tent or near continuous
CPB time
Crossclamp time
Previous graft status: None, occluded, stenosed, or patent
grafts to the LAD, circumflex, and RCA territories
Number of diseased vessels 
Number of new grafts 
Use of LITA at reoperation
Surgeon
Discussion
Dr Hendrick B. Barner (St Louis, Mo). Others have tout-
ed the benefits of retrograde cardioplegia for redo-CABG, but
this is the first report demonstrating a reduction in operative
mortality with its use. I have used antegrade-retrograde car-
dioplegia for coronary reoperations during the same time
frame but in about 80% of cases from the beginning. Your use
of retrograde cardioplegia was only 55% in 1997. Since it is
clearly helpful, it is surprising to me that its use has not been
greater. Has its use increased since then? If not, why? 
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I assume these data were generated by 6 or 7 operating sur-
geons. This poses questions regarding the distribution of cases
among those individuals and whether you entered the surgeon
into the analysis of risk factors for hospital mortality. 
You initiated this analysis to also determine the effect of
graft status on the risk of hospital death and found that it
was not a risk factor, which is contrary to some reports of
more than a decade ago. You also ligated or divided all dis-
eased vein grafts after the initial dose of antegrade cardio-
plegia, which I practiced some years ago but abandoned
because of my increasing use of all arterial conduits at reop-
eration and concern over perioperative hypoperfusion. Did
you not divide diseased vein grafts if they were replaced
with an arterial conduit? 
Contrary to the experience from the Cleveland Clinic and
the Massachusetts General Hospital, you did not find that
emergency timing was a risk factor for hospital death, where-
as it was a most important one at these institutions. This may
well be related to your definition of “emergency,” which com-
monly means transport to the operating theater directly from
the catheterization laboratory or the intensive care unit, as
opposed to your definition of “within 12 hours of the cardiac
event.” I would also wonder whether there were too few
patients in this category to provide meaningful data? 
Finally, I am curious about the use of tepid cardioplegic
solution, which was introduced by 2 of your coauthors. I
adopted this modality in 1995 with the modification of hav-
ing both the patient and cardioplegic solution at 33°C. I use it
in all operations on the heart and was surprised to see that its
usage remains uncommon at the Toronto General Hospital.
Would you care to comment on this? 
Dr Borger. Thank you very much, Dr Barner, for your
comments. I will try to answer your questions in sequence. 
The use of retrograde cardioplegia did increase over the 8
years of this study, and it continues to increase in redo-CABG
at our institution. 
The number of surgeons that were analyzed for this study
was 10. We did look at surgeon-specific operative mortality,
and there were some differences. However, there were no sig-
nificant outliers, that is, each one of the surgeons fell within the
95% confidence intervals of the group mean. Also, an interest-
ing point is that the surgeon with the lowest operative mortali-
ty in this group of patients used predominantly retrograde car-
dioplegia, but the surgeon with the second lowest operative
mortality used almost exclusively antegrade cardioplegia.
Therefore, it was not simply that the surgeons with the lowest
mortality used retrograde cardioplegia. In other words, this is
not a surgeon-specific result. I honestly believe that retrograde
cardioplegia is of benefit in redo-CABG surgery. 
Regarding your question whether or not we ligated all
saphenous vein grafts, there was one group of patients in
whom we did not use this technique because of a very impor-
tant article published by the Cleveland Clinic. According to
this article, in patients with a large noncritically stenosed
LAD vein graft that is going to be bypassed with a LITA, it is
better not to divide the vein grafts because of possible poor
perfusion of the LAD territory. Therefore, in these patients
we often left the saphenous vein graft in place.
With regard to the definition of operative timing, our defi-
nition is always a bit different from that of American studies.
We defined urgent timing as operations performed during the
same hospitalization stay as the initial admission for the car-
diac event and emergency timing as those operations per-
formed within 12 hours of a cardiac event, The risk of mor-
tality in patients undergoing urgent and emergency
operations was increased in our univariate analysis. However,
it fell out during the multivariable analysis. 
Finally, with regard to tepid cardioplegia use, the majority
of our surgeons at our institution do use cold antegrade blood
cardioplegia plus or minus retrograde cardioplegia. Of
course, we performed the Warm Heart Trial several years ago,
which showed some benefit with warm cardioplegia, but
there is always the worry about increased neurologic threat.
Tepid cardioplegia has been demonstrated by Dr Weisel and
his colleagues to possibly be superior temperature to cold or
warm cardioplegia. However, we think that cold cardioplegia
still gives us the best safety margin, which is often necessary
in these complicated redo-CABG operations. Therefore, I do
not believe that the number of patients receiving tepid car-
dioplegia will be increasing in the near future at our institu-
tion. Ideally, the number of patients who receive retrograde
cardioplegia during redo-CABG surgery will increase at our
institution. 
Dr D. Craig Miller (Stanford, Calif). I have a quick ques-
tion,
Dr Borger. What is happening to your redo-CABG
patients? You have long waiting lists in Canada, and I believe
your unit has gone from 1000 to 2000 or maybe nearly 3000
pump cases a year. Yet, your incidence of redo-CABG stayed
about the same, 100 or so a year. Are the patients requiring
redo-CABG going to other centers in Ontario or perhaps
across the lake?
Dr Borger. Before 1990, the number of total CABGs at
our institution did increase at a linear rate. However, the
number has been fairly constant over the 8 years of this
study, from 1990 to 1997. When we looked at the number
of redo-CABGs as a percentage of all of the CABG proce-
dures done, once again, it remained relatively constant over
this time period. 
This is in contrast to previous studies, in particular from the
Cleveland Clinic, that suggest that redo surgery may be
increasing in prevalence over time. I am not exactly sure why
our prevalence did not increase over these 8 years.
Presumably, it is related to improvements in medical man-
agement, particularly aggressive cholesterol-lowering man-
agement, and it may also be related to our increasing use of
additional arterial grafts, but that is only speculative at this
point. One other hospital in the Toronto area did perform pro-
gressively more redo-CABG operations over the 8-year time
period, so that may have affected our trends as well. 
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